[Pricing] compounded tirz pricing in my state, six months of receipts
The title is the argument: compounded tirz pricing in my state, six months of receipts. Here is the rest of it.
A 503A pharmacy compounds for an identified patient against a prescription. A 503B outsourcing facility registers with the regulator, may produce without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. The two are governed differently and the difference is not cosmetic.
On concentration, which is where I see people actually get hurt.
A compounded vial can be filled at a different concentration from the branded product you were previously using. If you carry over your old arithmetic — same number of units, different mg/mL — you draw a different amount and may not notice for weeks.
Read the label every time you switch. Redo the arithmetic on paper. Write the concentration on the vial. It is the same habit c/reconstitution keeps preaching and this is the case where it actually bites.
Why "compounded" is not "generic", written out because the confusion is constant.
A generic is an approved product demonstrated to be bioequivalent to a reference. A compounded preparation is made for a patient or, in the case of an outsourcing facility, under a different regulatory route entirely. It carries no equivalence claim and it is not required to demonstrate one.
That is not a quality judgement. Plenty of compounded preparations are made carefully in facilities with real testing programmes. It is a statement about what has and has not been established, and the difference matters when people assume the two are interchangeable.
Happy to answer the boring questions. Those are usually the ones worth asking.
best — the order this archive was captured in
Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.
ask what the beyond-use date is based on
Right, and the concentration genuinely can differ from the branded product, which breaks people’s arithmetic.
Is the compound still on the shortage list where you are?
the label on a compounded vial is a legal document, read it
ask which facility, then ask for their testing
Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.
The five questions worth asking before you commit to any compounded arrangement.
Which facility, by name. Whether it is a 503A pharmacy or a 503B outsourcing facility. What concentration is on the label. What the beyond-use date is based on. Whether there is potency testing on the finished preparation rather than only on the starting material.
All five are answerable in one email and the pattern of what comes back is more informative than any of the individual answers. An organisation with a quality system finds these questions ordinary.
shortage status changes and the whole arrangement changes with it
Switched between two compounded preparations and the concentration on the label was different. Redid the arithmetic on paper before drawing anything.
Kept the label from every vial. When the shortage status changed, having the paper trail made the conversation much shorter.
Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.
Concentration on the compounded vial was different from what I had been using and I nearly did the arithmetic on autopilot.
Asked for the beyond-use date basis and got a real answer with a stability reference attached. Not universal, apparently.
Same view. If the intake asked you nothing, the intake was a formality and you should factor that in.
a 503B has to register and report, so there is a paper trail to ask for
Yes. The shortage list is the legal hinge for the whole arrangement and its status is public.
The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.
Kept the label from every vial.
Agreed — and the follow-up question is what the beyond-use date is based on.
a telehealth intake that asks nothing has told you what it is
salt forms are the recurring argument and the answer is boring
salt forms are the recurring argument and the answer is boring
mikkel_correia is right about the concentration trap. It breaks arithmetic that has been reliable for months.
a telehealth intake that asks nothing has told you what it is
Disagreeing with this bit: registration is not equivalence, and the two get run together constantly.
- 1Kept the label from every vial. When the shortage status changed, having the…9 comments in this branch · started by u/sofia_nascimento